MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAITM


Ryan Allway

March 4th, 2021

Psychedelics, Top News


MagicMed Industries Inc. (CSE: MGIC reserved)(“MagicMed” or the “Company“) announced today a collaboration among the Company, Dr. Suran Goonatilake and Dr. Eric Nyberg, renowned thought leaders in artificial intelligence (“AI”).  Together the parties are building PsyAITM, a tool designed to provide comprehensive, pharmaceutical design, manufacturing, pharmacology predictive and validating methodologies in an effort to modernize psychedelic medicine.

The standard pharmaceutical candidate screening process is a consistent bottleneck in bringing standard pharmaceutical candidates to market and acts as a primary determinant of eventual clinical success or failure. This paradigm is particularly challenging in the psychedelics pharmaceutical sector, owing to a limited understanding of the mechanisms underlying observed clinical data.  Similarly, the correlation between the actual physical structure of psychedelic agents and patient outcomes is unknown. The strict regulatory regimes in place for the last five decades have only recently been relaxed and have inhibited critical basic research in this sector and put the already challenging drug development process at an even greater disadvantage.

Combining PsyAITM and the PsybraryTM, MagicMed’s large-scale novel molecule creation platform, creates an opportunity to accelerate the development of optimized pharmaceutical candidates, each tailored specifically for difficult-to-treat mental health indications.

MagicMed’s Chief Scientific Officer, Dr. Peter Facchini, stated “It is an exceptional opportunity, and indeed and honour, to be allayed with two internationally respected thought leaders in AI, upholding the Company’s core tenet of engaging with industry leaders. Dr. Suran Goonatilake and Dr. Eric Nyberg, whose ground-breaking developments have helped shaped aspects of AI for decades, have agreed to join us in solving a fundamental challenge: the quest to develop new therapies for devastating mental health conditions”.

Dr. Suran Goonatilake, Visiting Professor, UCL Centre for Artificial Intelligence, and co-founder of April 19 Discovery Inc., has a track record in developing new AI methods and applying them to address some of the world’s hardest problems. Through his PhD research in intelligent hybrid systems, he co-founded SearchSpace (acquired by Warburg Pincus), one of the world’s first AI platforms to detect complex patterns in financial transactions ranging from insider-dealing detection at stock exchanges to money laundering detection at retail banks.  Dr. Goonatilake commented, “2021 is an exciting point in history. Three major disciplines are converging: AI-driven drug-discovery, synthetic biology and the ‘psychedelic renaissance’ to treat mental health conditions. It’s very exciting to be at the nexus of this convergence.”

He added, “I am honoured to collaborate with Dr. Nyberg to take MagicMed’s library of psychedelic compounds – PsybraryTM – and apply deep-learning methods to move them along the pipeline towards APIs (active pharmaceutical ingredients). We believe that every AI module increases the value of a compound as a potential therapeutic by leveraging AI systems to replace human scientists and thereby reducing the time and cost to bring a therapeutic to market.”

Dr. Eric Nyberg, Chief Data Scientist at Cognistx (Cognistx.com) and Professor at Carnegie Mellon University, was a member of the original IBM Watson development team and also developed scalable architecture for multi-strategy question-answering systems. Dr. Nyberg stated, “It is my view that the need in society has never been greater for great minds to come together and pool resources to solve a serious and growing problem in society. I am pleased to have the opportunity to collaborate with Dr. Goonatilake and MagicMed, to build upon a classification and clustering matrix and ultimately deploy a tier-based model that designs structures, optimizes synthesis processes, and predicts biophysical properties from receptor binding and pharm/tox through to patient outcomes in distinct clinical indications. I believe that the need for, and thus value of, the development of this new tool we are building to revolutionize the psychedelic medicine sector cannot be overstated”.

Drs. Goonatilake’s and Nyberg’s contributions will be delivered through their AI companies, April 19 Discovery Inc. and Cognistx, respectively.

PsyAITM, PsybraryTM, MagicMedTM, and MagicMed IndustriesTM are trademarks of MagicMed Industries Inc., submitted for registration in the USA and Canada.

About MagicMed
MagicMed Industries intends to partner with pharmaceutical and other companies to develop and commercialize psychedelic-derived pharmaceutical candidates. MagicMed’s psychedelic derivatives library, the PsybraryTM, is anticipated to be an essential building block from which industry can develop new patented products. The initial focus of the PsybraryTM is on psilocybin and DMT derivatives, and it is then expected to be expanded to other psychedelics such as MDMA, LSD, mescaline, and ibogaine.

About Cognistx
Founded in 2015, Cognistx is a Pittsburgh-based applied AI company, building multi-strategy AI systems for clients across the U.S. Cognistx create AI-powered computer systems that can sense, learn, and act. The company founders are pioneers in the fields of automatic question-answering, speech processing, computer vision, natural language processing (NLP), and applied machine learning. The team at Cognistx is able to efficiently combine and customize the best advanced technologies- their AI building blocks – to create applications that extract meaningful insights to produce measurable impacts for their clients. VisitCognistx.com

About April 19 Discovery Inc.
April 19 is an AI-driven drug-discovery company entirely focused on developing and screening novel compounds for psychedelic medicine. The ‘psychedelic renaissance’ promises to provide much needed therapies to treat depression, PTSD, anxiety, addiction cessation and other mental health conditions. Salina is a division of April 19 that is developing AI-driven biomarkers (e.g. EEG analytics) to automatically detect adverse events (e.g. cardiac arrests) to increase safety in this emerging industry. A long-term goal is to fundamentally change the economics of this new sector by reducing clinical reliance on medical personnel and lower the cost-per-patient within FDA-approved treatment protocols. Visit www.april19.ai

MagicMed Industries Inc. 
Dr. Joseph Tucker
Chief Executive Officer
[email protected]
403-605-8747

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading